Skip to main content
Erschienen in: Osteoporosis International 6/2019

29.03.2019 | Review Article

Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies

verfasst von: A. Salari-Moghaddam, O. Sadeghi, A. H. Keshteli, B. Larijani, A. Esmaillzadeh

Erschienen in: Osteoporosis International | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

No study is available summarizing earlier publications on the association between metformin use and risk of fracture. This systematic review and meta-analysis were conducted to summarize earlier findings on the association between metformin use and risk of fracture.

Methods

We conducted a systematic search on all published articles up to October 2018 using online databases including PubMed/Medline, ISI Web of Science, and Scopus. Observational studies that considered metformin use as the exposure variable and bone fracture as the main outcome variable or as one of the outcome variables and participants included were 18 years and older were included in the systematic review. Publications in which hazard ratios (HRs), rate or risk ratios (RRs), or odds ratios (ORs) were reported as effect size were included in the meta-analysis.

Results

Totally, three cohort studies, one cross-sectional study, one nested case-control study, and one case-control study were included in this systematic review and meta-analysis. When seven effect sizes from six studies were combined, a significant inverse association between metformin use and risk of fracture was observed (RR 0.82; 95% CI 0.72, 0.93). No significant between-study heterogeneity was found (I2 = 22.4%, Pheterogeneity = 0.25). In addition, no evidence of publication bias was seen using Egger’s test (P = 0.99).

Conclusion

We found that metformin use was inversely associated with the risk of fracture.
Literatur
1.
Zurück zum Zitat Rivas A, Romero A, Mariscal-Arcas M, Monteagudo C, Feriche B, Lorenzo ML, Olea F (2013) Mediterranean diet and bone mineral density in two age groups of women. Int J Food Sci Nutr 64(2):155–161CrossRefPubMed Rivas A, Romero A, Mariscal-Arcas M, Monteagudo C, Feriche B, Lorenzo ML, Olea F (2013) Mediterranean diet and bone mineral density in two age groups of women. Int J Food Sci Nutr 64(2):155–161CrossRefPubMed
2.
Zurück zum Zitat Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRefPubMedPubMedCentral Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Feart C, Lorrain S, Ginder Coupez V, Samieri C, Letenneur L, Paineau D, Barberger-Gateau P (2013) Adherence to a Mediterranean diet and risk of fractures in French older persons. Osteoporos Int 24(12):3031–3041CrossRefPubMed Feart C, Lorrain S, Ginder Coupez V, Samieri C, Letenneur L, Paineau D, Barberger-Gateau P (2013) Adherence to a Mediterranean diet and risk of fractures in French older persons. Osteoporos Int 24(12):3031–3041CrossRefPubMed
4.
Zurück zum Zitat Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166(5):495–505CrossRefPubMed Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166(5):495–505CrossRefPubMed
5.
Zurück zum Zitat Palermo A, D’Onofrio L, Eastell R, Schwartz AV, Pozzilli P, Napoli N (2015) Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int 26(8):2073–2089CrossRefPubMed Palermo A, D’Onofrio L, Eastell R, Schwartz AV, Pozzilli P, Napoli N (2015) Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int 26(8):2073–2089CrossRefPubMed
6.
Zurück zum Zitat Gu Q, Gu Y, Yang H, Shi Q (2017) Metformin enhances osteogenesis and suppresses adipogenesis of human chorionic villous mesenchymal stem cells. Tohoku J Exp Med 241(1):13–19CrossRefPubMed Gu Q, Gu Y, Yang H, Shi Q (2017) Metformin enhances osteogenesis and suppresses adipogenesis of human chorionic villous mesenchymal stem cells. Tohoku J Exp Med 241(1):13–19CrossRefPubMed
7.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48(7):1292–1299CrossRefPubMed Vestergaard P, Rejnmark L, Mosekilde L (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48(7):1292–1299CrossRefPubMed
8.
Zurück zum Zitat Melton LJ III, Leibson CL, Achenbach SJ, Therneau TM, Khosla S (2008) Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 23(8):1334–1342CrossRefPubMedPubMedCentral Melton LJ III, Leibson CL, Achenbach SJ, Therneau TM, Khosla S (2008) Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 23(8):1334–1342CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Kanazawa I, Yamaguchi T, Yamamoto M, Sugimoto T (2010) Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab 28(5):554–560CrossRefPubMed Kanazawa I, Yamaguchi T, Yamamoto M, Sugimoto T (2010) Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab 28(5):554–560CrossRefPubMed
10.
Zurück zum Zitat Majumdar SR, Josse RG, Lin M, Eurich DT (2016) Does sitagliptin affect the rate of osteoporotic fractures in type 2 diabetes? Population-based cohort study. J Clin Endocrinol Metab 101(5):1963–1969CrossRefPubMedPubMedCentral Majumdar SR, Josse RG, Lin M, Eurich DT (2016) Does sitagliptin affect the rate of osteoporotic fractures in type 2 diabetes? Population-based cohort study. J Clin Endocrinol Metab 101(5):1963–1969CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Napoli N, Strotmeyer ES, Ensrud KE, Sellmeyer DE, Bauer DC, Hoffman AR, Dam TT, Barrett-Connor E, Palermo L, Orwoll ES et al (2014) Fracture risk in diabetic elderly men: the MrOS study. Diabetologia 57(10):2057–2065CrossRefPubMedPubMedCentral Napoli N, Strotmeyer ES, Ensrud KE, Sellmeyer DE, Bauer DC, Hoffman AR, Dam TT, Barrett-Connor E, Palermo L, Orwoll ES et al (2014) Fracture risk in diabetic elderly men: the MrOS study. Diabetologia 57(10):2057–2065CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Monami M, Cresci B, Colombini A, Pala L, Balzi D, Gori F, Chiasserini V, Marchionni N, Rotella CM, Mannucci E (2008) Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 31(2):199–203CrossRefPubMed Monami M, Cresci B, Colombini A, Pala L, Balzi D, Gori F, Chiasserini V, Marchionni N, Rotella CM, Mannucci E (2008) Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 31(2):199–203CrossRefPubMed
13.
Zurück zum Zitat Colhoun HM, Livingstone SJ, Looker HC, Morris AD, Wild SH, Lindsay RS, Reed C, Donnan PT, Guthrie B, Leese GP et al (2012) Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 55(11):2929–2937CrossRefPubMedPubMedCentral Colhoun HM, Livingstone SJ, Looker HC, Morris AD, Wild SH, Lindsay RS, Reed C, Donnan PT, Guthrie B, Leese GP et al (2012) Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 55(11):2929–2937CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat de Zegher F, Garcia Beltran C, Lopez-Bermejo A, Ibanez L (2018) Metformin for rapidly maturing girls with central adiposity: less liver fat and slower bone maturation. Horm Res Paediatr 89(2):136–140CrossRefPubMed de Zegher F, Garcia Beltran C, Lopez-Bermejo A, Ibanez L (2018) Metformin for rapidly maturing girls with central adiposity: less liver fat and slower bone maturation. Horm Res Paediatr 89(2):136–140CrossRefPubMed
15.
Zurück zum Zitat Hegazy SK (2015) Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women. J Bone Miner Metab 33(2):207–212CrossRefPubMed Hegazy SK (2015) Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women. J Bone Miner Metab 33(2):207–212CrossRefPubMed
16.
Zurück zum Zitat Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, Northcutt AR, Kravitz BG, Paul G, Cobitz AR, Nino AJ, Fitzpatrick LA (2013) Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab 98(4):1519–1528CrossRefPubMed Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, Northcutt AR, Kravitz BG, Paul G, Cobitz AR, Nino AJ, Fitzpatrick LA (2013) Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab 98(4):1519–1528CrossRefPubMed
17.
Zurück zum Zitat Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ, Grosse M, Fitzpatrick LA, Cobitz AR (2011) A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients. Diabetes Obes Metab 13(11):1036–1046CrossRefPubMed Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ, Grosse M, Fitzpatrick LA, Cobitz AR (2011) A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients. Diabetes Obes Metab 13(11):1036–1046CrossRefPubMed
18.
Zurück zum Zitat Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM, Williams NI, Coney P, Legro RS (2011) The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril 95(3):1059–1066CrossRefPubMed Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM, Williams NI, Coney P, Legro RS (2011) The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril 95(3):1059–1066CrossRefPubMed
19.
Zurück zum Zitat Dutta M, Pakhetra R, Garg M (2012) Evaluation of bone mineral density in type 2 diabetes mellitus patients before and after treatment. Med J Armed Forces India 68(1):48–52CrossRefPubMedPubMedCentral Dutta M, Pakhetra R, Garg M (2012) Evaluation of bone mineral density in type 2 diabetes mellitus patients before and after treatment. Med J Armed Forces India 68(1):48–52CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G, for the A Diabetes Outcome Progression Trial (ADOPT) Study Group (2008) Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care 31(5):845–851CrossRefPubMed Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G, for the A Diabetes Outcome Progression Trial (ADOPT) Study Group (2008) Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care 31(5):845–851CrossRefPubMed
21.
Zurück zum Zitat Kanazawa I, Yamaguchi T, Yano S, Yamamoto M, Yamauchi M, Kurioka S, Sugimoto T (2010) Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int 21(12):2013–2018CrossRefPubMed Kanazawa I, Yamaguchi T, Yano S, Yamamoto M, Yamauchi M, Kurioka S, Sugimoto T (2010) Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int 21(12):2013–2018CrossRefPubMed
22.
Zurück zum Zitat Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R, Sturmer T (2009) A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 94(8):2792–2798CrossRefPubMedPubMedCentral Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R, Sturmer T (2009) A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 94(8):2792–2798CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Napoli N, Schwartz AV, Schafer AL, Vittinghoff E, Cawthon PM, Parimi N, Orwoll E, Strotmeyer ES, Hoffman AR, Barrett-Connor E, Black DM, for the Osteoporotic Fractures in Men (MrOS) Study Research Group (2018) Vertebral fracture risk in diabetic elderly men: the MrOS study. J Bone Miner Res 33(1):63–69CrossRefPubMed Napoli N, Schwartz AV, Schafer AL, Vittinghoff E, Cawthon PM, Parimi N, Orwoll E, Strotmeyer ES, Hoffman AR, Barrett-Connor E, Black DM, for the Osteoporotic Fractures in Men (MrOS) Study Research Group (2018) Vertebral fracture risk in diabetic elderly men: the MrOS study. J Bone Miner Res 33(1):63–69CrossRefPubMed
24.
Zurück zum Zitat Puar TH, Khoo JJ, Cho LW, Xu Y, Chen YT, Chuo AM, Poh CB, Ng JM (2012) Association between glycemic control and hip fracture. J Am Geriatr Soc 60(8):1493–1497CrossRefPubMed Puar TH, Khoo JJ, Cho LW, Xu Y, Chen YT, Chuo AM, Poh CB, Ng JM (2012) Association between glycemic control and hip fracture. J Am Geriatr Soc 60(8):1493–1497CrossRefPubMed
25.
Zurück zum Zitat Wells GASB, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2009) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, Ottawa Wells GASB, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2009) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, Ottawa
26.
Zurück zum Zitat Sellmeyer DE, Civitelli R, Hofbauer LC, Khosla S, Lecka-Czernik B, Schwartz AV (2016) Skeletal metabolism, fracture risk, and fracture outcomes in type 1 and type 2 diabetes. Diabetes 65(7):1757–1766CrossRefPubMedPubMedCentral Sellmeyer DE, Civitelli R, Hofbauer LC, Khosla S, Lecka-Czernik B, Schwartz AV (2016) Skeletal metabolism, fracture risk, and fracture outcomes in type 1 and type 2 diabetes. Diabetes 65(7):1757–1766CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2008) Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 375(3):414–419CrossRefPubMed Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2008) Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 375(3):414–419CrossRefPubMed
28.
Zurück zum Zitat Schurman L, McCarthy AD, Sedlinsky C, Gangoiti MV, Arnol V, Bruzzone L, Cortizo AM (2008) Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 116(6):333–340CrossRefPubMed Schurman L, McCarthy AD, Sedlinsky C, Gangoiti MV, Arnol V, Bruzzone L, Cortizo AM (2008) Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 116(6):333–340CrossRefPubMed
29.
Zurück zum Zitat Zhen D, Chen Y, Tang X (2010) Metformin reverses the deleterious effects of high glucose on osteoblast function. J Diabetes Complicat 24(5):334–344CrossRefPubMed Zhen D, Chen Y, Tang X (2010) Metformin reverses the deleterious effects of high glucose on osteoblast function. J Diabetes Complicat 24(5):334–344CrossRefPubMed
Metadaten
Titel
Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies
verfasst von
A. Salari-Moghaddam
O. Sadeghi
A. H. Keshteli
B. Larijani
A. Esmaillzadeh
Publikationsdatum
29.03.2019
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 6/2019
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-019-04948-1

Weitere Artikel der Ausgabe 6/2019

Osteoporosis International 6/2019 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.